Hawaiʻi is short of physicians — but not of dermatologists. That is the paradox reported by Honolulu Civil Beat, and it cuts against the narrative most dermatology practices hear about access to specialty care in the United States.

The report frames a statewide physician shortage affecting Hawaiʻi's residents, while dermatology stands out as an exception with a comparatively high number of practicing specialists. For a specialty routinely described as undersupplied at the national level, a surplus in an island state with a dispersed, multi-island population is a data point worth examining.

The contrast matters for several reasons. First, it complicates workforce planning. If Hawaiʻi can sustain a dense dermatology workforce while other specialties lag, factors beyond simple physician supply — training pipeline, lifestyle draw, reimbursement mix, practice economics — are shaping the distribution. Hawaiʻi has long competed for physicians against mainland markets that offer higher compensation and lower cost of living, and the state's recruitment efforts have historically centered on primary care, surgery, and rural neighbor-island coverage rather than skin specialists.

Second, the surplus raises questions about access rather than raw headcount. A high count of dermatologists concentrated on Oʻahu may still leave patients on Hawaiʻi Island, Maui, Kauaʻi, Molokaʻi, or Lānaʻi with long travel times and waitlists for skin cancer screening and treatment. Skin cancer detection is a particular concern in a tropical, high-UV environment where cumulative sun exposure drives incidence of non-melanoma and melanoma skin cancers. Headline workforce numbers do not capture whether neighbor-island patients can get a suspicious lesion assessed within a clinically appropriate window, nor do they distinguish cosmetic-heavy practices from those accepting medical dermatology referrals and public insurance.

Third, the finding is a useful counterweight for policy debates. State and federal loan-repayment and incentive programs typically allocate resources by shortage designation. If dermatology in Hawaiʻi is comparatively well staffed while the state still reports an overall physician deficit, the shortfall likely sits in primary care, emergency medicine, psychiatry, and surgical subspecialties — areas where a missing physician translates directly into longer emergency waits and deferred care. Workforce policy that treats all specialties equally would misdirect scarce incentive dollars.

For dermatologists weighing practice decisions, the Hawaiʻi picture cuts both ways. A crowded specialist market can compress new-patient volumes and intensify competition for referrals, particularly in cosmetic and aesthetic segments where patient acquisition costs are already rising. At the same time, a strong local specialty presence builds referral networks, supports teledermatology infrastructure for neighbor-island outreach, and may sustain shared coverage arrangements that mainland solo practices struggle to maintain.

The report also invites a closer look at how Hawaiʻi's dermatology distribution evolved. Academic pipeline effects, the draw of the islands for physicians at earlier career stages, and the state's Pacific Rim patient mix all plausibly contribute. Civil Beat's framing — shortage overall, abundance in dermatology — suggests the state's physician crisis is one of composition and geography, not uniform scarcity.

What the headline data cannot yet answer is whether the dermatology surplus translates into measurable access gains: wait times for new medical dermatology visits, melanoma diagnosis intervals, or neighbor-island coverage rates. Those are the metrics that would tell patients, payers, and policymakers whether Hawaiʻi's well-staffed dermatology workforce is actually closing the skin-care access gap, and future workforce analyses from the state will need to track them.